Watch IMUX. Know when insiders buy.
One email the day a filing lands. Free.
IMUX
IMMUNIC, INC.
10.35
+0.23 +2.27%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
14
FLAG · shorts 14
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $141.2MP/E —DIV YIELD —FCF YIELD -62.35%REV TTM —NET INCOME −$111.6MNET CASH —52W 5.10 – 16.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$35.3M | −$34.1M | — | -0.80 | −$31M | $249K | −$31.2M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$33.2M | −$32.6M | — | -1.08 | −$17.3M | $2K | −$17.3M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$23.3M | −$19.3M | — | -0.07 | −$19.3M | $11K | −$19.3M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$26M | −$25.6M | — | -0.13 | −$20.1M | $67K | −$20.2M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$27.1M | −$26.8M | — | -2.03 | −$24.6M | $36K | −$24.6M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$26.8M | −$25.5M | — | -2.51 | −$21.8M | $47K | −$21.8M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$25.6M | −$25.2M | — | -0.25 | −$23M | $3K | −$23M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$25.7M | −$24.4M | — | -0.24 | −$20.8M | $50K | −$20.8M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$22.8M | −$21.4M | — | -0.21 | −$17M | $180K | −$17.2M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$23.9M | −$29.6M | — | -0.30 | −$24M | $31K | −$24M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$23.4M | −$21.6M | — | -0.48 | −$14M | $165K | −$14.2M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$23.6M | −$22.8M | — | -0.51 | −$17.3M | $44K | −$17.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$103.2M | −$97.2M | — | -0.62 | −$85.8M | $161K | −$86M | — | — |
| FY2024 · to Dec 31 | — | — | −$98.1M | −$100.5M | — | -1.00 | −$84.8M | $264K | −$85M | — | — |
| FY2023 · to Dec 31 | — | — | −$99.2M | −$93.6M | — | -2.11 | −$70.8M | $334K | −$71.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$119.5M | −$120.4M | — | -3.78 | −$65.1M | $112K | −$65.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$91.7M | −$92.9M | — | -3.93 | −$83.2M | $67K | −$83.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$49M | −$44M | — | -2.81 | −$46.1M | $146K | −$46.3M | — | — |
Every number comes from IMMUNIC, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.